About
Technology
Issues
FAQ
Links
Official Page
Androgen receptor degradation by the proteolysis-targeting chimera ARCC-4 outperforms enzalutamide in cellular models of prostate cancer drug resistance
Distribution of the number of citations over years.
site/software ©
exaly
; All materials licenced under
CC by-SA
.